{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007196","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.993486+00:00","generated_at":"2026-06-02T13:35:17.651531+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ArriVent Q1 net loss $17.4M; cash $317.4M; fully enrolled PACC cohort, initiated combo study","bullets":["Cash and equivalents $317.4M as of March 31, 2024, expected to fund operations into 2026.","Net loss $17.4M for Q1 2024 vs $12.2M in Q1 2023; R&D expense $17.0M vs $10.2M.","Fully enrolled Phase 1b FURTHER trial for firmonertinib in NSCLC EGFR PACC mutations; proof-of-concept data expected in 2024.","Initiated Phase 1b combo study of firmonertinib and ICP-189 (SHP2 inhibitor) for EGFR classical mutation NSCLC.","Appointed Kristine Peterson to Board; presented preclinical AACR data showing broad activity across uncommon EGFR mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007196","json":"https://secwatch.observer/filing/0001558370-24-007196.json","markdown":"https://secwatch.observer/filing/0001558370-24-007196.md","text":"https://secwatch.observer/filing/0001558370-24-007196.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/0001558370-24-007196-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/avbp-20240508x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T13:35:17.651531+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"adafdc87f0a8e5121387f12ac2351e8eee33a5dd","claim":"ArriVent BioPharma, Inc. reported first quarter ended March 31, 2024 results: net income $17.4 million.","evidence_excerpt":"Net loss was $17.4 million and $12.2 million for the quarters ended March 31, 2024 and 2023, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1868279/000155837024007196/0001558370-24-007196-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Net income","value":"$17.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}